MicuRx(SH:688373)2025-02-14 07:55Financial Performance - In 2024, the company achieved total operating revenue of RMB 130.27 million, a year-on-year increase of 43.51%[4] - The net profit attributable to the parent company was a loss of RMB 440.72 million, an increase in loss of RMB 19.60 million compared to the previous year[7] - Total assets at the end of 2024 were RMB 849.13 million, a decrease of 27.34% year-on-year[8] - The equity attributable to the parent company decreased by 47.37% year-on-year, amounting to RMB 438.96 million[5] - The basic earnings per share were -0.67 RMB, compared to -0.64 RMB in the previous year[4] - The net asset per share attributable to the parent company was 0.67 RMB, down 47.24% year-on-year[5] Research and Development - The company increased its investment in R&D, leading to higher R&D expenses during the reporting period[9] - The company continues to promote key R&D projects and actively market its core product, resulting in sustained high levels of loss[12] Business Growth - The increase in hospital coverage and prescription volume contributed to steady growth in main business revenue[12] Reporting Accuracy - There are no significant uncertainties affecting the accuracy of the performance report[13]